Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS Research and Therapy
Published in: AIDS Research and Therapy 1/2024

Open Access 01-12-2024 | Biomarkers | Research

Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine

Authors: Eisuke Adachi, Makoto Saito, Amato Otani, Michiko Koga, Hiroshi Yotsuyanagi

Published in: AIDS Research and Therapy | Issue 1/2024

Login to get access

Abstract

We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. The CD4/CD8 ratio and C-reactive protein did not change. There were transient decreases in CD8 and CD4 counts in the group that switched from the dolutegravir-based regimen, but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein (HDL) cholesterol increased, resulting in a decrease in the total-cholesterol to HDL cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol.
Appendix
Available only for authorised users
Literature
1.
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV Infection. PLoS Med. 2008;5(10):e203.CrossRefPubMedPubMedCentral
2.
Castillo-Mancilla JR, Brown TT, Erlandson KM, Palella FJ Jr., Gardner EM, Macatangay BJ, et al. Suboptimal adherence to combination antiretroviral therapy is Associated with higher levels of inflammation despite HIV suppression. Clin Infect Dis. 2016;63(12):1661–7.CrossRefPubMedPubMedCentral
3.
4.
Kettelhut A, Bowman E, Funderburg NT. Immunomodulatory and anti-inflammatory strategies to reduce comorbidity risk in people with HIV. Curr HIV/AIDS Rep. 2020;17(4):394–404.CrossRefPubMed
5.
Hamlyn E, Stöhr W, Cooper DA, Fisher M, Tambussi G, Schechter M, et al. The effect of short-course antiretroviral therapy initiated in primary HIV-1 Infection on interleukin-6 and D-dimer levels. Aids. 2015;29(11):1355–61.CrossRefPubMed
6.
Baker JV, Sharma S, Grund B, Rupert A, Metcalf JA, Schechter M, et al. Systemic inflammation, Coagulation, and clinical risk in the START Trial. Open Forum Infect Dis. 2017;4(4):ofx262.CrossRefPubMedPubMedCentral
7.
Yamamoto S, Saito M, Nagai E, Toriuchi K, Nagai H, Yotsuyanagi H, et al. Antibody response to SARS-CoV-2 in people living with HIV. J Microbiol Immunol Infect. 2021;54(1):144–6.CrossRefPubMed
8.
Ramirez LA, Daniel A, Frank I, Tebas P, Boyer JD. Seroprotection of HIV-infected subjects after Influenza A(H1N1) vaccination is directly associated with baseline frequency of naive T cells. J Infect Dis. 2014;210(4):646–50.CrossRefPubMedPubMedCentral
9.
Llibre JM, Cahn PE, Lo J, Barber TJ, Mussini C, van Welzen BJ, et al. Changes in inflammatory and atherogenesis biomarkers with the 2-Drug Regimen Dolutegravir Plus Lamivudine in antiretroviral Therapy-Experienced, virologically suppressed people with HIV-1: a systematic literature review. Open Forum Infect Dis. 2022;9(4):ofac068.CrossRefPubMedPubMedCentral
10.
Adachi E, Ikeuchi K, Koga M, Yotsuyanagi H. Changes in inflammatory biomarkers when switching from three-drug regimens to Dolutegravir Plus Lamivudine in people living with HIV. AIDS Res Hum Retroviruses. 2022;38(12):881–3.CrossRefPubMed
11.
Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 Infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021;8(11):e668–e78.CrossRefPubMed
12.
Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 Infection: 152-Week results from ATLAS-2 M, a randomized, Open-Label, phase 3b, Noninferiority Study. Clin Infect Dis. 2023;76(9):1646–54.CrossRefPubMedPubMedCentral
13.
Adachi E, Ikeuchi K, Koga M, Yotsuyanagi H. Background factors in people living with HIV in Japan who switch to cabotegravir plus rilpivirine: a pilot study. J Infect Chemother. 2023;29(1):109–11.CrossRefPubMed
14.
Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–e40.CrossRefPubMed
15.
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender men and Transgender women. N Engl J Med. 2021;385(7):595–608.CrossRefPubMedPubMedCentral
16.
Hadrup SR, Strindhall J, Kollgaard T, Seremet T, Johansson B, Pawelec G, et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol. 2006;176(4):2645–53.CrossRefPubMed
17.
Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8 + T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.CrossRefPubMedPubMedCentral
18.
Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(3):403–8.CrossRefPubMed
19.
20.
Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-Acting Cabotegravir and Rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112–23.CrossRefPubMed
Metadata
Title
Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine
Authors
Eisuke Adachi
Makoto Saito
Amato Otani
Michiko Koga
Hiroshi Yotsuyanagi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2024
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-023-00590-4

Other articles of this Issue 1/2024

AIDS Research and Therapy 1/2024 Go to the issue

Brief Communication

A call for change: addressing the implementation strategy using pre exposure Prophylaxis for combating the escalating HIV crisis in Zanzibar’s key populations

Research

Outcomes of antiretroviral treatment for 0-14-year-old children living with HIV in Ganzhou, China, 2006–2023

Research

Satisfaction of antiretroviral therapy services and its associated factors among adult clients attending antiretroviral therapy in Woliso town, Ethiopia

Brief Communication

Presence of tuberculosis symptoms among HIV-positive men who have sex with men (MSM) in Zimbabwe

Research

Factors influencing rapid antiretroviral therapy initiation in Jiulongpo, Chongqing, China: a retrospective cohort from 2018 to 2022

Research

Xpert HIV-1 qual point-of-care testing for HIV early infant diagnosis in Tanzania: experiences and perceptions of health care workers in a 2016 study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits